China's OTC Market: Cardiovascular Are Highly Concerned And Cold And Cough Remains The Most Common Health Issue
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - China's over-the-counter drug market has grown 10 to 15 percent since 2007 and to more than RMB 90 billion ($13 billion) in 2009, according to healthcare market intelligence provider IMS Health
You may also be interested in...
Winter Has Come: Big Pharma Cold And Cough Sales Drop By Half Following New China Policy
Multinational cold and cough OTC products have suffered a serious setback in China, as government restricts usage of drugs containing pseudoephedrine.
Winter Has Come: Big Pharma Cold And Cough Sales Drop By Half Following New China Policy
Multinational cold and cough OTC products have suffered a serious setback in China, as government restricts usage of drugs containing pseudoephedrine.
Boehringer Ingelheim Opens R&D Center In Shanghai; Sees Sales Growth From Products On NDRL Reimbursement List
SHANGHAI - Boehringer Ingelheim, the largest family-controlled pharma company, recently announced the opening of its Center of Competence in Shanghai. During the past year, the company invested €10 million to build the R&D center, which specializes in optimizing active pharmaceutical ingredients and chemical intermediates procured in China